[ÇÑÅõÁõ±Ç ÁøÈ«±¹] Á¦¾à/¹ÙÀÌ¿À µ¥Àϸ® ´º½º
¾È³çÇϼ¼¿ä ÇÑÅõÁõ±Ç Á¦¾à¹ÙÀÌ¿À ÁøÈ«±¹ÀÔ´Ï´Ù.
¢ºÀüÀÏ ¹Ì±¹ ÁÖ¿ä À妽º
* ´Ù¿ì +0.4% S&P Á¦¾à -0.3% ³ª½º´Ú ¹ÙÀÌ¿À -0.4%
¢ºÇØ¿Ü Peer ÀüÀÏ ÁÖ°¡
* ¼¿Æ®¸®¿Â °ü·Ã: Pfizer +0.2% J&J +0.2% Teva -0.8% Mylan -2.6%
* »ï¼º¹ÙÀÌ¿À °ü·Ã: Lonza +1.1% Merck -0.2% Roche -0.8% Amgen -0.6% Biogen -1%
* Çѹ̾àÇ° °ü·Ã: Sanofi -0.9% Spectrum +1.3%
* º¸Å彺: Allergan -0.1% Revance Therapeutic -1.5% Evolus -2.3%
* ±âŸ: Gilead Science -0.8% Regeneron -3.5% Abbvie -0.6% Celgene +0% Eli Lilly +0.4% CSL +0%
¢º±¹³» À̽´
* ³ªº¸Å¸, ¹Ì¿ë¡¤Ä¡·á Àü¹æÀ§ ÀûÀÀÁõ...±Û·Î¹ú Ç°¸ñ µµ¾à
http://bit.ly/2Hg12EU
* Ä¡¸ÅÄ¡·áÁ¦ ½ÃÀå ÀçÆí ¿¹°í¡¦'Äݸ°¾ËÆ÷' ¹Ý»çÀÌÀÍ Àü¸Á
http://bit.ly/2HfXOS0
* ºÐ½Äȸ°è¡¤¼ººÐº¯°æ ³í¶õ¡¦Á¦¾à¹ÙÀÌ¿ÀÁÖ, 5¿ùÀÇ Âù¹Ù¶÷
http://bit.ly/2JgnsYY
* 'ERR¥ã ´Ü¹éÁú' Ç¥Àû ¹ÌºÐÈ°©»ó¼±¾Ï ½Å¾à¹°Áú ¹ß±¼
http://bit.ly/2VyXTsI
* ¸Þµð³ë ¡°½Å°æÅðÇ༺Áúȯ Ÿ±ê NSC ¼¼Æ÷Ä¡·áÁ¦ °³¹ß¡±
http://bit.ly/2HiT5h5
* '°æ³²Á¦¾à Àμö 9ºÎ´É¼±' ¹ÙÀÌ¿ÀÁ¦³×ƽ½º, ¾î¶² ȸ»ç?
http://bit.ly/2JgnSi0
* °¡À̵å¶óÀΠŸ°í µîÀç 'Á©ÀÜÁî', ´ëÀå¿° °ø·« START
http://bit.ly/2VfhZmM
* Çѱ¹Äݸ¶, ½Ç·Î½ºÅºCR Á¤Á¶ÁØ...½ÃÀåÆǵµ ÁÖ¸ñ
http://bit.ly/2PZzer6
¢ºÇØ¿Ü À̽´
* Statement on policy advancements to help bring interchangeable biosimilars to market
http://bit.ly/2VwevkX
* ³ë¹ÙƼ½º ¡®·¹º¼·¹À̵塯 ÀϺΠ»ý»êºÐ Ú¸¼ ȸ¼ö
http://bit.ly/2Yq7z5Q
* ±Û·Î¹ú Á¦¾à»ç ½Ã°¡ÃÑ¾× ¡®ºò 3¡¯ J&J¤ýÈÀÌÀÚ¤ý·Î½´
http://bit.ly/2LGLfmS
* BMS, ¿Éµðº¸ ±³¸ð¼¼Æ÷Á¾ ÀûÀÀÁõ È®´ë ÀÓ»ó 3»ó ½ÇÆÐ
http://bit.ly/2Q2p7lC |